Mantle Cell Lymphoma

Questions discussed in this category

Would you consider replacing ibrutinib with acalabrutinib or zanubrutinib in the TRIANGLE regimen for MCL in a patient with atrial fibrillation or high risk coronary syndromes who is otherwise fit for aggressive induction therapy?

TRIANGLE study

2 Answers available

Following the BRUIN data in mantle cell lymphoma, will you routinely treat with pirtobrutinib following a covalent BTKi?

Is the data sufficient to change your practice?

2 Answers available

Will you recommend pirtobrutinib following a prior covalent BTKi in patients with cardiac comorbidities?

Does cumulative exposure to BTKi increase potential risk of cardiac toxicity?

2 Answers available

What subsequent therapies did patients receive after progressing on pirtobrutinib in the mantle cell BRUIN trial population?

Should pirtobrutinib be viewed as a bridge to CAR-T or transplant or a destination therapy?

2 Answers available

Are there biomarkers or other factors to help predict which patients with MCL are most likely to benefit, or not, from pirtobrutinib following a prior covalent BTKi?

How do you predict which patients may be in a high risk group and less likely to benefit from a second BTKi?

2 Answers available

What are the factors that convince you to not immediately treat mantle cell lymphoma and to follow a course of "active surveillance"?

Is there a specific Ki67 percentage? P53-negativity?

3 Answers available

How would you approach treatment for a R/R mantle cell lymphoma patient with a history of autoimmune hepatitis who has progressed on both a covalent and non-covalent BTKi?

1 Answer available

In light of the TRIANGLE data at ASH, how should we now approach a transplant-eligible patient with a new diagnosis of aggressive mantle cell lymphoma?

2 Answers available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10

Outcome of deferred initial therapy in mantle-cell lymphoma.

J. Clin. Oncol., 2009 Oct 05

Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma.

Ann. Oncol.,

Observation as the initial management strategy in patients with mantle cell lymphoma.

Cancer Res., 2010 Feb 02

Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma.

Haematologica, 2019-04

Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma.

N Engl J Med, 2022 Jun 03

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.

J Hematol Oncol, 2021 Oct 30

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.

J Clin Oncol, 2017 Jan 17

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

J Clin Oncol, 2023 May 16

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.

Related Topics